A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)

NCT05013229 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

679

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: IcoSema
DRUG: Insulin glargine
DRUG: insulin aspart

Sponsor

Novo Nordisk A/S